Results 21 to 30 of about 1,029,988 (373)

Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir

bioRxiv, 2020
The pandemic of Corona Virus Disease 2019 (COVID-19) caused by SARS-CoV-2 has become a global crisis. The replication of SARS-CoV-2 requires the viral RNA-dependent RNA polymerase (RdRp), a direct target of the antiviral drug, Remdesivir.
W. Yin, C. Mao, X. Luan, D. Shen, Q. Shen, H. Su, Xiao-xi Wang, F. Zhou, Wenfeng Zhao, M. Gao, Shenghai Chang, Yuanchao Xie, Guanghui Tian, He-wei Jiang, S. Tao, Jingshan Shen, Yi Jiang, Hualiang Jiang, Yechun Xu, Shuyang Zhang, Yan Zhang, H. Eric Xu   +21 more
semanticscholar   +1 more source

Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms

Science Translational Medicine, 2022
The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
Laura J. Stevens, A. Pruijssers, Hery W. Lee, Calvin J. Gordon, E. Tchesnokov, Jennifer Gribble, Amelia S. George, Tia M. Hughes, Xiaotao Lu, Jiani Li, Jason K. Perry, D. Porter, T. Cihlář, T. Sheahan, R. Baric, M. Götte, M. Denison   +16 more
semanticscholar   +1 more source

Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase

Frontiers in Immunology, 2022
GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral bioavailability of GS‐441524 poses a challenge to its anti-SARS-CoV-2 efficacy ...
Zhonglei Wang, Zhonglei Wang, Liyan Yang, Xian-qing Song   +3 more
doaj   +1 more source

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

Journal of Translational Medicine, 2020
Background SARS-CoV-2 is a RNA coronavirus responsible for the pandemic of the Severe Acute Respiratory Syndrome (COVID-19). RNA viruses are characterized by a high mutation rate, up to a million times higher than that of their hosts.
M. Pachetti, B. Marini, F. Benedetti, F. Giudici, E. Mauro, P. Storici, C. Masciovecchio, S. Angeletti, M. Ciccozzi, R. Gallo, D. Zella, R. Ippodrino   +11 more
semanticscholar   +1 more source

Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP

Proceedings of the National Academy of Sciences of the United States of America, 2021
Significance While the current COVID-19 pandemic continues, the US Food and Drug Administration (FDA) has approved only one drug against the virus—remdesivir.
K. Naydenova, K. W. Muir, Long-Fei Wu, Ziguo Zhang, F. Coscia, M. Peet, P. Castro-Hartmann, P. Qian, K. Sader, Kyle C. Dent, D. Kimanius, J. Sutherland, J. Löwe, D. Barford, C. Russo   +14 more
semanticscholar   +1 more source

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Journal of Biological Chemistry, 2020
Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Calvin J. Gordon, E. Tchesnokov, E. Woolner, Jason K. Perry, Joy Y. Feng, D. Porter, M. Götte   +6 more
semanticscholar   +1 more source

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Journal of Biological Chemistry, 2020
Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome–coronavirus 2 (CoV-2).
Calvin J. Gordon, E. Tchesnokov, Joy Y. Feng, D. Porter, M. Götte   +4 more
semanticscholar   +1 more source

Cell penetrable humanized-VH/V(H)H that inhibit RNA dependent RNA polymerase (NS5B) of HCV. [PDF]

PLoS ONE, 2012
NS5B is pivotal RNA dependent RNA polymerase (RdRp) of HCV and NS5B function interfering halts the virus infective cycle. This work aimed to produce cell penetrable humanized single domain antibodies (SdAb; VH/V(H)H) that interfere with the RdRp activity.
Kanyarat Thueng-in, Jeeraphong Thanongsaksrikul, Potjanee Srimanote, Kunan Bangphoomi, Ornnuthchar Poungpair, Santi Maneewatch, Kiattawee Choowongkomon, Wanpen Chaicumpa   +7 more
doaj   +1 more source

SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective

Journal of Biomolecular Structure and Dynamics, 2020
New treatment against SARS-CoV-2 now is a must. Nowadays, the world encounters a huge health crisis by the COVID-19 viral infection. Nucleotide inhibitors gave a lot of promising results in terms of its efficacy against different viral infections.
Abdo A. Elfiky
semanticscholar   +1 more source

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Science, 2020
A wrench in the works of COVID-19 Understanding the inner workings of the virus that causes coronavirus disease 2019 (COVID-19) may help us to disrupt it. Yin et al. focused on the viral polymerase essential for replicating viral RNA.
W. Yin, W. Yin, C. Mao, Xiaodong Luan, Xiaodong Luan, D. Shen, Qingya Shen, H. Su, Xiao-xi Wang, F. Zhou, Wenfeng Zhao, M. Gao, Shenghai Chang, Yuan Chao Xie, Guanghui Tian, He wei Jiang, Sheng-ce Tao, Jingshan Shen, Yi Jiang, Hualiang Jiang, Yechun Xu, Shuyang Zhang, Shuyang Zhang, Yan Zhang, H. E. Xu   +24 more
semanticscholar   +1 more source